Patient Organisations & Groups

Our commitment to improving the health of people around the world is a common objective that LogixX Pharma shares with healthcare providers and patients.

LogixX Pharma recognises the crucial role that patient groups and healthcare providers play in enhancing and extending the lives of patients, particularly in the area of s. We are committed to establishing strong alliances with patient groups and organisations, thus building further knowledge and awareness, and improving diagnosis, treatment and prevention of s.

By supporting patient advocacy groups and organisations that strive for improved patient care, LogixX Pharma , always promoting the highest levels of transparency and integrity, strengthens the power of patients to influence positive change in healthcare.


Patient groups supported by LogixX Pharma :

EURODIS (s Europe)
EURODIS is a non-governmental patient-driven alliance of patient organisations representing 624 patient organisations in 58 countries. We are the voice of 30 million people affected by s throughout Europe.

RARE Corporate Alliance™
The RARE Corporate Alliance™ is a collaboration of stakeholders committed to helping advance efforts benefiting the community and its constituents.

UK (RDUK)
RDUK is the national alliance for people with s and all who support them.  It was established by Genetic Alliance UK, the national charity of over 160 patient organisations supporting all those affected by genetic conditions, in conjunction with other key stakeholders in November 2008.

National Organization for Rare Disorders (NORD)
NORD), a 501(c)(3) organization, is a unique federation of voluntary health organizations dedicated to helping people with rare "orphan" diseases and assisting the organizations that serve them. NORD is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and service.

International Conference on s and Orphan Drugs (ICORD)
ICORD is an international society for all individuals active in s and/or orphan drugs, including health care, research, academic, industry, patient organizations, regulatory authorities, health authorities, and public policy professionals.

The International Patient Organisation for Primary Immunodeficiencies (IPOPI)
IPOP is the Association of national patient organisations dedicated to improving awareness, access to early diagnosis and optimal treatments for primary immunodeficiency (PID) patients worldwide.

See a full list of patient groups and organisations supported by LogixX Pharma